Literature DB >> 1887674

Active immunity is seen as a reduction in the cell response to oral live vaccine.

A Kantele1, J M Kantele, H Arvilommi, P H Mäkelä.   

Abstract

Oral immunization elicits a response of antibody-secreting cells (ASC) in the peripheral blood; these cells are believed to originate in the mucosa and hence give information on the mucosal immune response. We have shown earlier that oral booster immunization is followed by an elevated ASC response reflecting an immunologic memory. In the present study we show that a booster dose of a live bacterial vaccine given at a time of active mucosal immunity elicits a low ASC response only. This is probably because the multiplication of the live vaccine is inhibited in the gut, resulting in a low actual dose of the antigen. This situation may be an example of the protective immunity manifested when an orally immunized person encounters the pathogen in nature, and could be used to assess the protective immunity.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1887674     DOI: 10.1016/0264-410x(91)90130-x

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  13 in total

1.  Antibody-secreting cells in human peripheral blood after oral immunization with an inactivated enterotoxigenic Escherichia coli vaccine.

Authors:  C Wennerås; A M Svennerholm; C Ahrén; C Czerkinsky
Journal:  Infect Immun       Date:  1992-07       Impact factor: 3.441

2.  Evaluation in volunteers of a candidate live oral attenuated Salmonella typhi vector vaccine.

Authors:  D M Hone; C O Tacket; A M Harris; B Kay; G Losonsky; M M Levine
Journal:  J Clin Invest       Date:  1992-08       Impact factor: 14.808

3.  Attenuation and immunogenicity of Deltacya Deltacrp derivatives of Salmonella choleraesuis in pigs.

Authors:  M J Kennedy; R J Yancey; M S Sanchez; R A Rzepkowski; S M Kelly; R Curtiss
Journal:  Infect Immun       Date:  1999-09       Impact factor: 3.441

4.  Dose-dependent circulating immunoglobulin A antibody-secreting cell and serum antibody responses in Swedish volunteers to an oral inactivated enterotoxigenic Escherichia coli vaccine.

Authors:  M Jertborn; C Ahrén; A M Svennerholm
Journal:  Clin Diagn Lab Immunol       Date:  2001-03

5.  Safety and immunogenicity of a proteosome-Shigella flexneri 2a lipopolysaccharide vaccine administered intranasally to healthy adults.

Authors:  L F Fries; A D Montemarano; C P Mallett; D N Taylor; T L Hale; G H Lowell
Journal:  Infect Immun       Date:  2001-07       Impact factor: 3.441

Review 6.  Immunology of gut mucosal vaccines.

Authors:  Marcela F Pasetti; Jakub K Simon; Marcelo B Sztein; Myron M Levine
Journal:  Immunol Rev       Date:  2011-01       Impact factor: 12.988

7.  Intestinal immune responses in patients infected with enterotoxigenic Escherichia coli and in vaccinees.

Authors:  C Wennerås; F Qadri; P K Bardhan; R B Sack; A M Svennerholm
Journal:  Infect Immun       Date:  1999-12       Impact factor: 3.441

8.  Safety and immunogenicity of two different lots of the oral, killed enterotoxigenic escherichia coli-cholera toxin B subunit vaccine in Israeli young adults.

Authors:  D Cohen; N Orr; M Haim; S Ashkenazi; G Robin; M S Green; M Ephros; T Sela; R Slepon; I Ashkenazi; D N Taylor; A M Svennerholm; A Eldad; J Shemer
Journal:  Infect Immun       Date:  2000-08       Impact factor: 3.441

9.  Assessment of the duration of protection in Campylobacter jejuni experimental infection in humans.

Authors:  David R Tribble; Shahida Baqar; Daniel A Scott; Michael L Oplinger; Fernando Trespalacios; David Rollins; Richard I Walker; John D Clements; Steven Walz; Paul Gibbs; Edward F Burg; Anthony P Moran; Lisa Applebee; A Louis Bourgeois
Journal:  Infect Immun       Date:  2010-01-19       Impact factor: 3.441

Review 10.  Reassessment of the impact of mucosal immunity in infection with the human immunodeficiency virus (HIV) and design of relevant vaccines.

Authors:  J Mestecky; S Jackson
Journal:  J Clin Immunol       Date:  1994-09       Impact factor: 8.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.